Department of Cardiovascular Medicine, University of Massachusetts Chan Medical School, Worcester, MA, 01655, USA.
Indian Heart J. 2023 Mar-Apr;75(2):91-97. doi: 10.1016/j.ihj.2023.01.011. Epub 2023 Feb 1.
Cardiovascular diseases, a global health issue, claim the lives of many every year. Lifestyle changes and genetic predisposition are the key drivers for the development of CVDs. In many of the patients, the disease is detected at the end stage making heart transplantation the only treatment option. Hence every attempt should be made to identify the risk at an early stage and initiate preventive measures to improve the quality of their life. Biomarkers are one of the critical factors that aid in the early diagnosis of CVDs. More specific and highly sensitive biomarkers have been discovered lately and have been employed for prognosis and diagnosis of CVDs. The present review briefs about the various categories of cardiovascular biomarkers with emphasis on novel biomarkers and discusses the biomarkers employed for different purposes in CVDs. The biomarkers have also helped in identifying COVID-19 patients with increased risk for developing cardiovascular complications. Being non-invasive makes biomarkers advantageous over other methods for evaluating the pathophysiological status of CVDs.
心血管疾病是一个全球性的健康问题,每年都会夺走许多人的生命。生活方式的改变和遗传易感性是 CVD 发展的关键驱动因素。在许多患者中,疾病在晚期才被检测到,使得心脏移植成为唯一的治疗选择。因此,应该尽一切努力在早期识别风险,并采取预防措施来提高他们的生活质量。生物标志物是有助于早期诊断 CVD 的关键因素之一。最近发现了更具体和高度敏感的生物标志物,并已用于 CVD 的预后和诊断。本综述简要介绍了各种心血管生物标志物类别,重点介绍了新型生物标志物,并讨论了用于 CVD 不同目的的生物标志物。生物标志物还有助于识别 COVID-19 患者发生心血管并发症的风险增加。生物标志物具有非侵入性,因此在评估 CVD 的病理生理状态方面优于其他方法。